Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients)

Yıl: 2014 Cilt: 10 Sayı: 2 Sayfa Aralığı: 98 - 105 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients)

Öz:
Objective: Breast cancer is the most common type of cancer and the leading cause of cancer related deaths in women in Turkey, as elsewhere around the world. However, detailed and systematic demographics, data on clinical and pathological characteristics, and treatment were largely unavailable in Turkey until now. This paper is intended to provide an analysis of clinical and pathological data on women registered in the National Breast Cancer Database (Ulusal Meme Kanseri Veri Tabanı [UMKVT]), established within Turkish Federation of Breast Diseases Societies (TMHDF) and available for use in Turkey since 2005. Materials and Methods: Clinical and pathological data on breast cancer patients registered online in the database from May 01, 2005 to May 01, 2011 were investigated. Parameters examined in patients included age, menopausal status, distribution of clinical and pathological stage, histological type, tumor diameter, histological grades, regional lymphatic stage, estrogen (ER), progesterone (PR), HER-2 receptors and molecular subtypes. Analysis results of these parameters were compared with literature data and discussed. Results: A total of 13,240 patients with breast cancer since April 07, 1992 were included in the study, and 99% of them were female. Female breast cancer patients whose requisite parameters had been completely entered in the database were included in the analysis. The mean age was 51.6 years (±12.6; range 12-97), 17% of them were younger than 40 years of age, and 45% were premenopausal. According to an analysis of age groups at diagnosis, the frequency of cancer peaked at the 45 - 49 age group with 16.7%, declining to 7.6% in the 65-69 age group, and then rose again. Most of the patients (78.7%) had invasive ductal, 7.8% were invasive lobular cancers, 9.8% were invasive mixed cancers (invasive ductal + invasive lobular), and 4% were other histological types (e.g. inflammatory, intracystic papillary, mucinous, etc.), respectively. Half of them (50%) had grade III histology. According to an analysis of pathological stages of all breast cancers (stage 0 - IV), 5% were stage 0, 27% were stage I, 44% were stage II, 21% were stage III, and 3% were stage IV breast cancer, respectively. The mean tumor diameter was 2.5 cm (±1.6; range 0.1-20 cm). The rates of lymphatic stages were pN0 50%, pN1 28%, pN2 15%, and pN3 7%, respectively. ER, PR, and HER-2 receptors were positive in 70%, 59%, and 23% of patients. A subtype analysis of tumors showed that 62% were type luminal A. This was followed by subtypes luminal B (15%), triple negative (15%), and HER-2 positive (8.5%). Conclusion: As a conclusion patients with breast cancer in our breast cancer registry program were younger, and had more advanced disease, and worse prognostic factors than patients in developed countries
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Ozmen V. Breast Cancer in Turkey. İstanbul: Yelken Basim Yayin Sanayi ve Ticaret Ltd. Sirketi, 2013.
  • Wagner G. History of cancer registration. 1991. Available from: http:// www.iarc.fr/en/publications/pdfs-online/epi/sp95/sp95-chap2.pdf
  • Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-2917. (PMID: 21351269) [CrossRef]
  • Eser SY. Cancer registry and cancer data centers. In: Murat Tuncer, ed. Cancer Control in Turkey. Ankara: Onur Matbaacılık, 2008.
  • Ozmen V. Breast cancer in Turkey and in the world. J Breast Health 2008; 4:6-12.
  • Dillon DA, Guidi AJ, Schnitt SJ. Pathology of invasive breast cancer. In: Harris JR, Lipmann ME, Morrow M, and Osborne CK, eds. Diseases of the Breast. Philadelphia: Wolters Kluwer/Lippincott Williams&Wilkins, 2010.
  • American Joint Committee on Cancer. AJCC Cancer Staging Manual, chapter 32, Springer, Berlin, Germany, 7th edition, 2010. Available from: URL: http://www.scribd.com/doc/41422083/Complete-AJCC-CancerStaging-Manual-7e-Text.
  • O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010; 16; 6100-6110. (PMID: 21169259) [CrossRef]
  • Ozmen V, Anderson BO. The challenge of breast cancer in low- and middle-income countries—implementing the breast health global initiative guidelines. US Oncology 2008:76-79.
  • http://globocan.iarc.fr/factsheets/cancers/all.asp
  • http://seer.cancer.gov
  • Fidaner C, Eser SY, Parkin DM. Incidence in Izmir in 1993-1994; First results from Izmir cancer registry. Eur J Cancer 2001; 37:83-92. (PMID: 11165134) [CrossRef]
  • Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast Cancer Before Age 40 Years. Semin Oncol 2009; 36:237-249. (PMID: 19460581) [CrossRef]
  • American Cancer Society. Breast Cancer Facts & Figures 2009-2010. Available from: http://www.cancer.org/acs/groups/content/@nho/documents/document/f861009final90809pdf.pd.
  • Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PSY. Spectrum of Breast Cancer in Asian Women. World J Surg 2007; 31:1031-1040. (PMID: 17387549) [CrossRef]
  • www.tuik.gov.tr
  • Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26:3324-3330. (PMID: 18612148) [CrossRef]
  • Liukkonen S, Leidenius M, Saarto T, Sjöström-Mattson J. Breast cancer in very young women. Eur J Surg Oncol 2011; 37:1030-1037. (PMID: 21937191) [CrossRef]
  • Neuschatz AC, DiPetrillo T, Safaii H, Price LL, Schmidt-Ullrich RK, Wazer DE. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 2003; 97:30-39. (PMID: 12491502) [CrossRef]
  • Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, Foekens JA, Zhang Y, Wang Y, Marcom K, Marks JR, Mukherjee S, Nevins JR, Blackwell KL, Potti A. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One 2008; 3:e1373. (PMID: 18167534) [CrossRef]
  • de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341:1039- 1043. (PMID: 8096955) [CrossRef]
  • Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I and II breast cancer. J Clin Oncol 1994; 12:888-894. (PMID: 8164038)
  • Lari SA, Kuerer HM. Kuerer. Biological markers in DCIS and risk of breast recurrence: A systematic review. J Cancer 2011; 2:232-261. (PMID: 2155238) [CrossRef]
  • Ozmen V, Ozkan-Gurdal S, Kayhan A, Ozaydin N, Cabioglu N, Ozcinar B, Aribal E. Successful results of a population-based organized mammography screening program in a developing country: The Turkish experience. December 10-14, 2013, San Antonio Breast Cancer Symposium 2013, San Antonio, Tx, USA.
  • Ozmen V. İnvaziv duktal karsinom. In: Cem Terzi, ed. Türk Cerrahi Derneği Temel ve Klinik Cerrahi Kitabı. Available from: URL: http:// www.tcdcerrahi.org/fulltext.php?id=340
  • Gurdal SO, Karanlik H, Cabioglu N, Ozcinar B, Yavuz E, Tuzlali S, Ozmen V. Positive or close margins in breast conserving surgery: Is reexcision always necessary? Eur J Surg Oncol 2012; 38:399-406. (PMID: 22440741) [CrossRef]
  • Ellis IO, Humphreys S, Michell M, Pinder SE, Wells CA, Zakhour HD; UK National Coordinating Commmittee for Breast Screening Pathology; European Commission Working Group on Breast Screening Pathology. Best Practice No 179. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. J Clin Pathol. 2004; 57:897- 902. (PMID: 15333647) [CrossRef]
  • Molino A, Giovannini M, Auriemma A, Fiorio E, Mercanti A, Mandara M, Caldara A, Micciolo R, Pavarana M, Cetto GL. Pathological, biological and clinical characteristics, and surgical management of elderly women with breast cancer. Crit Rev Oncol Hematol 2006; 59:226-233. (PMID: 16533603) [CrossRef]
  • Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356:1670-1674. (PMID: 17442911) [CrossRef]
  • Vandorpe T, Smeets A, Van Calster B, Van Hoorde K, Leunen K, Amant F, Moerman P, Deraedt K, Brouckaert O, Van Huffel S, Wildiers H, Christiaens MR, Neven P. Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients. Breast Cancer Res Treat 2011; 128:429-435. (PMID: 21562708) [CrossRef]
  • Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 2010; 28:92-98. (PMID: 19933921) [CrossRef]
  • Yu J, Dabbs DJ, Shuai Y, Niemeier LA, Bhargava R. Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics. Am J Clin Pathol 2011; 136:88-97. (PMID: 21685036) [CrossRef]
  • Kiderlen M, Bastiaannet E, Walsh PM, Keating NL, Schrodi S, Engel J, van de Water W, Ess SM, van Eycken L, Miranda A, de Munck L, van de Velde CJ, de Craen AJ, Liefers GJ. Surgical treatment of early stage breast cancer in elderly: an international comparison. Breast Cancer Res Treat 2012; 132:675-682. (PMID: 22119939) [CrossRef]
  • Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980; 45:2917- 2924. (PMID: 7388735) [CrossRef]
  • García-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, Mazepa-Sikora D, Kordek R, Lukaszek S, Sherman ME. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 2006; 95:123-129. (PMID: 16755295) [CrossRef]
  • Mise I, Vucić M, Maricević I, Sokcević M, Curić-Jurić S. Histologic subtypes of invasive lobular carcinoma in correlation with tumor status and hormone receptors. Acta Clin Croat 2010; 49:275-281. (PMID: 21462816)
  • Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis. BMC Cancer 2010; 10:191. (PMID: 20459777) [CrossRef]
  • Albain KS, Allred DC, Clark GM. Breast cancer outcomes and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994; 16:35-42. (PMID: 7999467)
  • Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005; 104:1575-1579. (PMID: 16134178) [CrossRef]
  • Warner E. Clinical practice. Breast-cancer screening. N Engl J Med 2011; 365:1025-1032. (PMID: 21916640) [CrossRef]
  • Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. In Vivo 2007; 21:673- 638. (PMID: 17708365)
  • Ferrero-Poüs M, Hacène K, Bouchet C, Le Doussal V, Tubiana- Hulin M, Spyratos F. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000; 6: 4745-4754. (PMID: 11156229)
  • Hoff ER, Tubbs RR, Myles JL, Procop GW. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 2002; 117:916-921. [CrossRef]
  • Carey LA, Perou CM, Gene arrays, prognosis, and therapeutic interventions. In Diseases of the Breast, Jay R Harris, Marc E Lippman, Monica Morrow, C Kent Osborne edts. 4th ed. Pp.458-472, chapter 32 Lippincott&Wilkins,a Wolters Kluwer , Philadelphia, USA, 2010.
  • Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A.Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 2009; 20:628-635. (PMID: 19074747) [CrossRef]
APA ÖZMEN V (2014). Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). , 98 - 105.
Chicago ÖZMEN Vahit Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). (2014): 98 - 105.
MLA ÖZMEN Vahit Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). , 2014, ss.98 - 105.
AMA ÖZMEN V Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). . 2014; 98 - 105.
Vancouver ÖZMEN V Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). . 2014; 98 - 105.
IEEE ÖZMEN V "Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients)." , ss.98 - 105, 2014.
ISNAD ÖZMEN, Vahit. "Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients)". (2014), 98-105.
APA ÖZMEN V (2014). Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). Meme Sağlığı Dergisi, 10(2), 98 - 105.
Chicago ÖZMEN Vahit Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). Meme Sağlığı Dergisi 10, no.2 (2014): 98 - 105.
MLA ÖZMEN Vahit Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). Meme Sağlığı Dergisi, vol.10, no.2, 2014, ss.98 - 105.
AMA ÖZMEN V Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). Meme Sağlığı Dergisi. 2014; 10(2): 98 - 105.
Vancouver ÖZMEN V Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). Meme Sağlığı Dergisi. 2014; 10(2): 98 - 105.
IEEE ÖZMEN V "Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients)." Meme Sağlığı Dergisi, 10, ss.98 - 105, 2014.
ISNAD ÖZMEN, Vahit. "Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients)". Meme Sağlığı Dergisi 10/2 (2014), 98-105.